A Case of Acquired Hemophilia A and Congenital Hemophilia B
Sickle Cell Anemia Therapeutics Market 2023 Size And Forecast To 2031
The MarketWatch News Department was not involved in the creation of this content.
Mar 29, 2023 (The Expresswire) -- Sickle Cell Anemia Therapeutics Marketinformation for each competitor includes (Emmaus Medical, Sangamo Biosciences, Micelle BioPharma, Ironwood Pharmaceuticals, Prolong Pharmaceuticals, Addmedica, Bioverativ, Bluebird Bio, Novartis, Gamida Cell, GlycoMimetics, Imara, Pfizer, Modus Therapeutics, Global Blood Therapeutics) Company Profile, Main Business Information, SWOT Analysis, Price and Gross Margin, Market Share, Retailing, Consumer and Retail industry and has 113 pages in it.
"Global Sickle Cell Anemia Therapeutics market size was valued at USD 4119.88 million in 2022 and is expected to expand at a CAGR of 19.39% during the forecast period, reaching USD 11933.98 million by 2028."
Short Description About Sickle Cell Anemia Therapeutics Market:
The global Sickle Cell Anemia Therapeutics market size was valued at USD 4119.88 million in 2022 and is expected to expand at a CAGR of 19.39% during the forecast period, reaching USD 11933.98 million by 2028.
The report combines extensive quantitative analysis and exhaustive qualitative analysis, ranges from a macro overview of the total market size, industry chain, and market dynamics to micro details of segment markets by type, application and region, and, as a result, provides a holistic view of, as well as a deep insight into the Sickle Cell Anemia Therapeutics market covering all its essential aspects.
For the competitive landscape, the report also introduces players in the industry from the perspective of the market share, concentration ratio, etc., and describes the leading companies in detail, with which the readers can get a better idea of their competitors and acquire an in-depth understanding of the competitive situation. Further, mergers and acquisitions, emerging market trends, the impact of COVID-19, and regional conflicts will all be considered.
In a nutshell, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the market in any manner.
Sickle Cell Anemia Therapeutics Market 2023 research is a key process that helps businesses gather and analyze information about their target Sickle Cell Anemia Therapeutics market, customers, competitors, and industry trends. Ask for Sample Report
Here Are Some Important Aspects of Sickle Cell Anemia Therapeutics Market 2023-2028: -
Define the Research Objectives: The first step in Sickle Cell Anemia Therapeutics market is to define the research objectives. This involves determining the specific questions that need to be answered and the information that needs to be gathered.
Identify the Target Market: Businesses need to identify their target Sickle Cell Anemia Therapeutics market and understand their needs, preferences, and behaviors. This can involve segmenting the market based on factors such as demographics, psychographics, and geographic location.
Select the Research Methodology: There are many different Sickle Cell Anemia Therapeutics market methodologies that can be used, such as surveys, focus groups, and observational research. The methodology selected will depend on the research objectives and the type of data that needs to be collected.
Collect Data: Once the Sickle Cell Anemia Therapeutics market methodology has been selected, data can be collected using various techniques such as online surveys, phone interviews, or in-person focus groups. It is important to ensure that the data collected is reliable, valid, and representative of the target market.
Analyze the Data: Once the data has been collected, it needs to be analyzed to identify trends, patterns, and insights. This can involve statistical analysis or qualitative analysis of open-ended responses.
Get a Sample PDF of report @ https://www.Marketgrowthreports.Com/enquiry/request-sample/22368731
Draw Conclusions and Make Recommendations: Based on the analysis of the data, businesses can draw conclusions and make recommendations for future actions. This could include changes to product offerings, marketing strategies, or business operations.
Continuously Monitor and Adapt: Markets are constantly changing, so it is important for businesses to continuously monitor their performance and adapt their strategies as needed to stay competitive.
Overall, Sickle Cell Anemia Therapeutics market is an important process that can provide businesses with valuable insights and inform important business decisions.
Topmost manufacturers/ Key player/ Economy by Business Leaders Leading Players of Irritable Bowel Syndrome Treatment Market Are:
● Emmaus Medical ● Sangamo Biosciences ● Micelle BioPharma ● Ironwood Pharmaceuticals ● Prolong Pharmaceuticals ● Addmedica ● Bioverativ ● Bluebird Bio ● Novartis ● Gamida Cell ● GlycoMimetics ● Imara ● Pfizer ● Modus Therapeutics ● Global Blood TherapeuticsGet a Sample Copy of the Sickle Cell Anemia Therapeutics Report 2023
Complete Sickle Cell Anemia Therapeutics Market Report
The global Complete Sickle Cell Anemia Therapeutics Market report examines various tendencies, obstructions, and challenges faced by the key competitors of Complete Sickle Cell Anemia Therapeutics market. The report has been constructed considering the major outcomes and consequences of the market.
Applications covered in the report are:
● Child ● AdultThis is based on the existing Sickle Cell Anemia Therapeutics market conditions and past data. Researchers have analysed every type of data and the participants, as well as, principals apart from geological areas and product type.
Types covered in the report are:
● Blood Transfusion ● Pharmacotherapy ●Why Companies Worldwide Rely on us to Grow and Put up with Revenues?
Sickle Cell Anemia Therapeutics market Expertise: Companies may partner with other companies that have specific expertise or knowledge in an area that the first company lacks. Sickle Cell Anemia Therapeutics market Cost savings: Collaborating with another company can help to reduce costs for both parties. Sickle Cell Anemia Therapeutics market Access to new: Partnering with a company that has a strong presence in a new market can help a company expand its reach and customer base. Sickle Cell Anemia Therapeutics market Innovation: Collaborating with other companies can lead to the development of new products, services, or technologies that can help to drive growth and revenue. Sickle Cell Anemia Therapeutics market Resources: By partnering with another company, a company can gain access to additional resources, such as funding or talent that can help them achieve their growth and revenue goals.
Get a Sample PDF of report @ https://www.Marketgrowthreports.Com/enquiry/request-sample/22368731
How the COVID-19 Pandemic and the Russia-Ukraine Conflict?
Supply Chain Disruptions: The COVID-19 pandemic and the ongoing conflict between Russia and Ukraine could disrupt supply chains, leading to shortages of goods and materials. This could impact the ability of B2B companies to produce and deliver products to their customers. Changes in consumer behavior: The pandemic has led to significant changes in consumer behavior, with more people shopping online and prioritizing health and safety. This could lead to shifts in demand for certain types of products and services, which could impact B2B companies that supply those products and services.
Economic Uncertainty: The pandemic and the conflict between Russia and Ukraine could lead to economic uncertainty, which could impact the willingness of businesses to invest in new projects and purchases. This could lead to a slowdown in B2B sales and revenue growth. Political instability: The conflict between Russia and Ukraine could lead to political instability in the region, which could have wider impacts on global trade and economic activity. This could create challenges for B2B companies that rely on international markets and supply chains.
TO KNOW HOW COVID-19 PANDEMIC AND RUSSIA UKRAINE WAR WILL IMPACT THIS MARKET - REQUEST SAMPLE
Here Are The Important Points Covered In The Sickle Cell Anemia Therapeutics Market:
● Find out the industry will change till 2028 according to our predictions ● Understand the historical, current and future prospects of the Sickle Cell Anemia Therapeutics Market ● Understand how sales volumes, Global share and growth of the Sickle Cell Anemia Therapeutics Market will occur in the next five years. ● Read product descriptions of Sickle Cell Anemia Therapeutics products, along with report scopes and upcoming trends in the industry. ● Learn about key growth factors of the Sickle Cell Anemia Therapeutics industry ● Get a comprehensive analysis of the drivers, risks, opportunities and restrains to growth of the Sickle Cell Anemia Therapeutics ● Get to know about the leading Market players, both current and emerging in the Global Sickle Cell Anemia TherapeuticsGet a Sample PDF of report @ https://www.Marketgrowthreports.Com/enquiry/request-sample/22368731
Sickle Cell Anemia Therapeutics
● What are the important RandD (Research and Development) factors and data identifications to responsible for rising market share? ● What are future investment opportunities in the in Sickle Cell Anemia Therapeutics landscape analysing price trends? ● Which are most dynamic companies with ranges and recent development within Irritable Bowel Syndrome Treatment Market till 2028? ● In what way is the market expected to develop in the forthcoming years? ● What are the principle issues that will impact development, including future income projections? ● What are market opportunities and potential risks associated with Irritable Bowel Syndrome Treatment by analysing trends?Major Points from Table of Contents
Major Points from Table of Contents
Global Sickle Cell Anemia Therapeutics Market Research Report 2023-2028, by Manufacturers, Regions, Types and Applications
1 Introduction1.1 Objective of the Study1.2 Definition of the Market1.3 Market Scope1.3.1 Market Segment by Type, Application and Marketing Channel1.3.2 Major Regions Covered (North America, Europe, Asia Pacific, Mid East and Africa)1.4 Years Considered for the Study (2017-2028)1.5 Currency Considered (U.S. Dollar)1.6 Stakeholders
2 Key Findings of the Study
3 Market Dynamics3.1 Driving Factors for this Market3.2 Factors Challenging the Market3.3 Opportunities of the Global Sickle Cell Anemia Therapeutics Market (Regions, Growing/Emerging Downstream Market Analysis)3.4 Technological and Market Developments in the Sickle Cell Anemia Therapeutics Market3.5 Industry News by Region3.6 Regulatory Scenario by Region/Country3.7 Market Investment Scenario Strategic Recommendations Analysis
4 Value Chain of the Sickle Cell Anemia Therapeutics Market
4.1 Value Chain Status4.2 Upstream Raw Material Analysis4.3 Midstream Major Company Analysis (by Manufacturing Base, by Product Type)4.4 Distributors/Traders4.5 Downstream Major Customer Analysis (by Region)
Get a Sample Copy of the Sickle Cell Anemia Therapeutics Market Report 2023
5 Global Sickle Cell Anemia Therapeutics Market-Segmentation by Type6 Global Sickle Cell Anemia Therapeutics Market-Segmentation by Application
7 Global Sickle Cell Anemia Therapeutics Market-Segmentation by Marketing Channel7.1 Traditional Marketing Channel (Offline)7.2 Online Channel
8 Competitive Intelligence Company Profiles
9 Global Sickle Cell Anemia Therapeutics Market-Segmentation by Geography
9.1 North America9.2 Europe9.3 Asia-Pacific9.4 Latin America
9.5 Middle East and Africa
10 Future Forecast of the Global Sickle Cell Anemia Therapeutics Market from 2023-2028
10.1 Future Forecast of the Global Sickle Cell Anemia Therapeutics Market from 2023-2028 Segment by Region10.2 Global Sickle Cell Anemia Therapeutics Production and Growth Rate Forecast by Type (2023-2028)10.3 Global Sickle Cell Anemia Therapeutics Consumption and Growth Rate Forecast by Application (2023-2028)
11 Appendix11.1 Methodology12.2 Research Data Source
And More…
Get a Sample PDF of report @ https://www.Marketgrowthreports.Com/enquiry/request-sample/22368731
Key Reasons to Purchase
● To gain insightful analyses of the market and have comprehensive understanding of the global Sickle Cell Anemia Therapeutics Market and its commercial landscape. ● Assess the production processes, major issues, and solutions to mitigate the development risk. ● To understand the most affecting driving and restraining forces in the Sickle Cell Anemia Therapeutics Market and its impact in the global market. ● Learn about the Sickle Cell Anemia Therapeutics Market strategies that are being adopted by leading respective organizations. ● To understand the future outlook and prospects for the Sickle Cell Anemia Therapeutics Market. ● Besides the standard structure reports, we also provide custom research according to specific requirementsPurchase this Report (Price 3250 USD for a Single-User License) https://www.Marketgrowthreports.Com/purchase/22368731
Contact Us:
Market Growth Reports
Email : sales@marketgrowthreports.Com
Web: www.Marketgrowthreports.Com
Phone : US +(1) 424 253 0946 / UK +(44) 203 239 8187
For More Related Reports Click Here :What is the outlook for the future of the Vendor Managed Inventory (VMI) industry, and what trends are likely to shape its evolution in the next few years?
What are some of the key applications of Smart Plastering Robot in market, and how are they likely to impact the market in the coming years?
What factors have contributed to the growth of the Mobile Virtual Network Operator market in recent years?
What factors have contributed to the growth of the Residential Roofing market in recent years?
How does a Architectural Design Software Market make money?
How much is the Gesture Recognition industry worth?
How big is the Sports Nutrition market?
Press Release Distributed by The Express Wire
To view the original version on The Express Wire visit Sickle Cell Anemia Therapeutics Market 2023 Size and Forecast to 2031
COMTEX_427910165/2598/2023-03-29T21:27:54
Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.Com. You can also contact MarketWatch Customer Service via our Customer Center.
The MarketWatch News Department was not involved in the creation of this content.
HOW TO AVOID SICKLE CELL ANEMIA
In recent times the fear of sickle cell disease is the beginning of wisdom to young couples who see their future together, but when there is a symptom of sickle cell in one, that relationship comes to a halt.
There are several types of sickle cell disease. The most common are: Sickle Cell Anemia (SS), Sickle Hemoglobin-C Disease (SC), Sickle Beta-Plus Thalassemia and Sickle Beta-Zero Thalassemia.
When a child inherits one substitution beta globin genes (the sickle cell gene) from each parents, the child has Sickle Cell Anemia (SS). Populations that have a high frequency of sickle cell anemia are those of African and Indian descents.
Individuals with Sickle Hemoglobin-C Disease (SC) have a slightly different substitution in their beta globin genes that produces both hemoglobin C and hemoglobin S. Sickle Hemoglobin-C disease may cause similar symptoms as sickle cell anemia but less anemia due to a higher blood count level. Populations that have a high frequency of sickle hemoglobin-C disease are those of West African, Mediterranean and Middle Eastern descents. Individuals with Sickle Beta Thalassemia (SB) disease also contain substitutions in both beta globin genes. The severity of the disease varies according to the amount of normal beta globin produced. When no beta globin is produced, the symptoms are almost identical to sickle cell anemia, with severe cases needing chronic blood transfusions. Populations that have a high frequency of Sickle Beta Thalassemia are those of Mediterranean and Caribbean descents. Through research, hemoglobin D, which is a different substitution of the beta globin gene, has been found to interact with the sickle hemoglobin gene. Individuals with Sickle Hemoglobin-D disease (SD) have moderately severe anemia and occasional pain episodes. Populations that have a high frequency of sickle hemoglobin-D disease are those of Asian and Latin American descents. And finally, Sickle Hemoglobin-O Disease. Hemoglobin O, another type of substitution in the beta globin gene, also interacts with sickle hemoglobin. Individuals with sickle hemoglobin- O disease (SO) can have symptoms of sickle cell anemia. Populations that have a high frequency of sickle hemoglobin-O disease are those of Arabian, North African and Eastern Mediterranean descents.
The most common of them all, sickle cell anemia, is an inherited condition that causes a type of faulty hemoglobin in red blood cells. It is the most common blood disorder passed down from parents to children. People with this disorder have a typical hemoglobin molecules called hemoglobin S, which can distort red blood cells into sickles, crescent moon or make them shapeless.
The Red Blood vessel carries oxygen to all parts of the body. In someone who has SCD, the red blood cells become hard and sticky and look like a C – shaped farm tool unlike the healthy red blood cell which is round shaped.
The sickle cells die early, which causes a constant shortage of red blood cells and when they travel through small blood vessels, they get stuck and clog the blood flow. This causes pain and other problems like infection, acute chest syndrome and stroke to its victim, which can be known as sickle cell crisis.
Most SCD patients do not manifest clinically till about age of six month when the level of hemoglobin F (HbF) begins to fall. They may present with pallor, jaundice, hepatosplenomegaly and swelling of dorsal of hands/ feet ( hand foot syndrome ) failure to thrive, infections, sickle cell habits, etc.
According to WHO, the African region is mostly affected by this disease. Also, the majority of children with the most severe form of the disease die before the age of five, usually from an infection or severe blood loss. However, in countries such as Cameroon, Republic of Congo, Gabon, Ghana and Nigeria, the prevalence is between 20% to 30% while in some parts of Uganda, it is as high as 45%.
A recent study by Nwogoh etal in Benin city, revealed an SCD prevalence of 2.39% and a carrier rate of about 23%.
Most times a person suffering from SCD has some physical attributes that ranges from a normal build to a tall lanky physique depending on the clinical severity. In childhood, sickle cell patients are shorter than normal, puberty is often delayed and considerable growth takes place in late adolescence such that adults with SCD are at least tall as normal. Many of these physical changes are due to the chronic hypothermia associated with severe anemia.
This disease has a great effect on the liver. This effect of SCD on the liver manifests as liver dysfunction often referred to as sickle cell hepatopathy. It occurs predominantly in patients with SCD and to a lesser extent in patients with HbC diseases and HbS Thalassemia. This liver dysfunction encompasses a range of hepatic pathology arising from the primary SCD process and complications of its treatment.
The primary disease process that may lead to liver dysfunction includes anemia, suckling of red cells in the Sinusoid, swollen kuffer cells, fibrin deposits and healing thrombosis leading to obstruction of blood flow in the liver. Consequences of treatment such as blood transfusion and antibiotics therapy can also lead to liver dysfunction complications of multiple blood transfusion like iron overload, acute and chronic infection with hepatitis B and C are also important causes of liver dysfunction in SCD. Third generation Calphalosporins are known to sometimes crystallize in the gallbladder leading to choleithiasis.
However, you can do several things that can keep Sickle cell crisis from occurring: don't drink a lot of alcohol. Don't smoke. If you do smoke. Exercise regularly but not so much that you become really tired. When you exercise, drink lots of fluids. Drink at least eight 12-ounce glasses of water a day during warm weather and reduce or avoid stress. Talk to your doctor if you're depressed or have problems with your family or job. Treat any infection as soon as it occurs. When in doubt, see your doctor. Wear warm clothes outside in cold weather and inside in air-conditioned rooms during hot weather. Also, don't swim in cold water. Try to be positive about yourself. Tell your doctor if you think you might have a sleep problem, such as snoring or if you sometimes stop breathing during sleep. If you have another medical condition, like diabetes, get treatment and control the condition. If you are pregnant or plan to become pregnant, get early prenatal care and travel only in commercial airplanes. If you have to travel in an unpressurized aircraft, talk to your doctor about extra precautions.
Most institutions in Nigeria lack day care settings for management of sickle cell crisis; however, this high mortality disease can be managed with antibiotics, blood transfusion also known as stem cell transplant. Bone marrow transplant is ultimately the only known cure for Sickle cell disease, but finding a donor is often difficult and the procedure could be costly and sometimes life-threatening complications may be involved.
New SCD carriers can be avoided through premarital screening and genetic counselling, prenatal diagnosis, preconceptional diagnosis and implantation of normal embryos after in vitro fertilisation, and in utero therapy using stem cell transplantation. Prevention of the disease through carrier identification and genetic counselling remains the only realistic approach to reduce the impact of the disease and allows better use of available resources in the low-income countries where the condition is most prevalent. Programmes of population screening and genetic counselling can have a major impact on the birth rate of children with SCD and other genetic diseases. The prospective control of SCD by heterozygote detection through premarital screening, which is vital to the identification of the couples at risk, is of utmost importance. The success of such a programme to a large extent depends on the SCD knowledge in the community, the understanding of the full consequences of having a sickler child, and people's attitude towards genetic screening and counselling.
Chinenye Anichebe, Gaduwa Estate, Dudu- Abuja
Managing Sickle Cell Disease
With improved quality of life and good management, persons with the sickle cell disease can live normal lives and achieve their aspirations. Martins Ifijeh writes
Tunde and his wife Kemi both have the AS genotype. They knew this before they got married, but were optimistic they would not give birth to children with SS genotype. They assumed worst still, they would rather have AS children, along with AA children. Their love was strong. Not even a genotype result few days to their wedding could break them. In their minds, since love conquers all, it will this time conquer the SS genotype when they start having babies.
Truly, it looked that way when their first child arrived. He had all shades of healthiness. He is AS, meaning, like their parents, he has the sickle cell trait. He wasn’t living with the disease, only with the traits. It was the least the parents prayed for. AA or on the alternative AS.
But their love couldn’t conquer the SS genotype in their second child. He is SS, and it took the parents over a year to notice this reality. They had celebrated his delivery after noticing he was just as healthy as his elder brother. But as months went by, everything began to change.
“In the very first few months, we didn’t notice he was different from his brother. All we saw was a healthy baby. So we concluded he must either have the AA or an AS genotype. Either way, we were planning to stop having babies just after two kids,†says Tunde.
“But as months went by, we started to notice he was different. His hands and feet were always warmer than usual, his feet unusually swollen, he was experiencing lack of sleep and loss of appetite, and most significantly, he would often cry for no just reason.â€
It was at this point the Tunde’s decided to take him to the hospital where he was diagnosed with the sickle cell disease, a condition that affects about 150,000 newborns in Nigeria yearly.
“I and my wife immediately realised what we feared most has come upon us. We didn’t know what else to do than to ask the doctor all possible questions on management, treatment or even cure. We didn’t want our son to go through the pain we know persons with the condition go through. We also feared for his life, as persons with the condition are often said to die young,†he added.
But the doctor assured them that gone were the days when children die from the disease, especially because of proper management. “We left the hospital fully armed that day, knowing that with proper management, our son will live a normal life and as well grow into old age.
“I was told he could be cured through a stem cell or bone marrow transplant, which is a tall order because of the financial implication and significant risk involved, but on the alternative, we should properly manage him, an approach that will make him as healthy as his brother,†he said.The Tunde’s decided to take the second option since the transplant, which is a definitive cure for the condition, is expensive for them.
“Our son is nine years old now and he is living very fine. We make sure he eats healthily, takes drugs when necessary, and does not involve in unnecessary strenuous activities that will sap his energy. We also make sure his teachers understand this, and help us put him in check in school. By making his health a priority, he is living well,†he added.
Tunde’s family is not the only ones with a child living with sickle cell disease. Millions of families across the country are grappling with the disease, with majority knowing just little about the disease and its management.
According to the World Health Organisation (WHO), Nigeria accounts for about 75 per cent of infant sickle cell cases in the continent with over 100,000 children dying from the disease every year in the country, while 40 million Nigerians are carriers and an estimated one million persons living with sickle cell disorder, making it a prevalence rate that has resulted in Nigeria commonly referred to as the country with the highest level of sickle cell disorder in the world.
Despite the high incidence of the disease, little is still known by Nigerians, especially those in rural and sub- urban areas, on the cause, management, prevention and a possible stem cell and bone marrow treatment.
Experts are of the opinion that the high death rate of the disease is highly preventable if there is proper management culture. They specifically advocate for increased awareness by stakeholders, Ministry of Health, health institutions, non-governmental organisations and public spirited individuals.
According to the Research Director, Fair Needs Africa, Lagos, Dr. Reuben Ogala, there exist proper management plans, such that persons living with it can lead normal lives and grow into old age. “Gone are the days when sickle cell disease is a death sentence. A sickle cell person should work closely with his or her doctor, eat good food and reduce unnecessary stress that could predispose them to crisis.
“In the United States, the life expectancy rate of a sickle cell person is 63 years, whereas the life expectancy of a person even without the disease in Nigeria is less about 50 years.
This, therefore tells you that with proper management, a sufferer can live even longer and healthier than someone without the disease,†he added.
He also explained that the disease can be prevented through genetic counselling, adding that when intending couples are educated on the disease, genotypes, risks, among others, it will help them in making informed decisions on whether or not to marry someone with sickle cell disease, the trait or someone with AA genotype.
Ogala, said that when both parents have the AS genotype, there was possibility of one in every four of their children having the SS genotype which is the sickle cell disorder; a diseases such a person will live with throughout his or her entire life.
He explained that a child born of the AS genotype has the sickle cell trait and can as well give birth to someone with the trait or someone who has the sickle cell disorder.
He believed that someone with AS genotype poses no threat until he or she mates with someone who also has the AS genotype or worse still, someone with SS genotype.
According to him, there are other situations where the sickle cell trait is combined with other hemoglobinopathies; abnormalities of the hemoglobin in the blood, which in itself poses a threat.
He said the major issues emanating from sickle cell disorder affect children more, as their tolerance level was low compared to that of adults, making them more at risk of the disease.
According to experts, sickle cell anemia is a disorder of the blood that causes the red blood cells to blow into a sickle shape.
These cells however do not carry oxygen efficiently to areas of the body where it is needed. Normal red blood cells have a 120-day life span, but people born with sickle cell disease have sickle-shaped blood cells that usually live not more than 20 days.
These sickle cells can get stuck in blood vessels, blocking blood flow and less blood flow can damage the body’s organs, muscles, and bones, sometimes leading to life-threatening conditions.
Also lending her voice, the National Director of the Sickle Cell Foundation of Nigeria, Dr. Annette Akinsetein, in an interview with THISDAY during one of their programmes, noted that in Nigeria, not many children with the disease grow into adulthood because of low awareness and management culture in the country.
She said gone were the days when SCD was a death sentence. “With proper information, the disease can be managed successfully, while the victim live a normal life.â€
She said contrary to beliefs in some areas that the disease was caused by witchcraft or ogbanje, that it was of genetic origin, which through counselling may be prevented, as the genotype of both parents play the role on whether their child will have the disease or not.
She called on the government to come up with newborn screening policy where SCD can be detected early in children. “This is done in the United Kingdom and the United States, and it has greatly helped in reducing number of crisis or deaths arising from it.
Shedding more light on how to tackle the disease, the former permanent secretary, Ministry of Health, Lagos State, and pioneer Chief Medical Director, Lagos State University Teaching Hospital (LASUTH), Dr. Olufemi Olugbile, had earlier explained to THISDAY that due to the medical care available now, people hardly die young as it used to be because majority are living into full adults and even growing old.
According to him, people should be aware of their own genotype and that of their prospective partners.
“Knowing the risks involved hopefully reduces the prevalence of it. Inasmuch as counselling has a major role to play, one cannot make a law that, if the partners’ genotype is not compatible, then they cannot get married. It should only be advisory. People should either take it or reject it. But generally, awareness is the key to reducing the disease,†he added.
Comments
Post a Comment